Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de fase II para avaliar o NH102 para depressão (NH102-21)

20 de setembro de 2026 atualizado por: Jiangsu Nhwa Pharmaceutical Co., Ltd.

Um multicêntrico, randomizado, duplo, dummy duplo, placebo e ensaio clínico de fase II de exploração da dose, para avaliar a eficácia e a segurança do NH102 no tratamento da depressão

This study is a multicenter, randomized, double-blind, double-dummy, parallel-group, dose-finding Phase II clinical trial with placebo and active comparator duloxetine . It is designed to preliminarily assess the efficacy and safety of NH102 in patients with major depressive disorder and to provide the basis for the design of Phase III clinical trials.

Visão geral do estudo

Descrição detalhada

This trial consists of three periods: a screening period (up to 2 weeks), a double-blind treatment period (6 weeks), and a tapering-off period/safety follow-up (1 week). The screening period may last up to 14 days and a minimum of 1 day.

Baseline assessments will be conducted prior to randomization to confirm the eligibility of participants. A total of 240 patients with depression will be randomly assigned in a 1:1:1:1:1 ratio to three experimental drug groups (10 mg, 20 mg, and 30 mg), one active control group (duloxetine hydrochloride capsules 60 mg ), or one placebo group. The double-blind treatment period will last for 6 weeks, during which participants will take the assigned medications according to the specified dosing regimen and will be followed up at the end of weeks 1, 2, 4, and 6. After the treatment period, participants will enter a 1-week tapering-off period and will undergo safety follow-up at the end of week 7.

Tipo de estudo

Intervencional

Inscrição (Real)

243

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Anhui
      • Hefei, Anhui, China, 230000
        • Anhui Mental Health Center
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100096
        • Beijing Huilongguan Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 400036
        • Chongqing Mental Health Center
    • Fujian
      • Xiamen, Fujian, China, 361012
        • Xiamen Xianyue Hospital
    • Guangdong
      • Guangzhou, Guangdong, China, 510370
        • The Affiliated Brain Hospital of Guangzhou Medical University
      • Shenzhen, Guangdong, China, 518118
        • Shenzhen Kangning Hospital
    • Hebei
      • Baoding, Hebei, China, 071000
        • Hebei Mental Health Hospital
    • Henan
      • Xinxiang, Henan, China, 453000
        • The Second Affiliated Hospital of Henan Medical University
      • Zhumadian, Henan, China, 463000
        • Zhumadian Second People's Hospital
    • Hunan
      • Changsha, Hunan, China, 410007
        • Hunan Second people's Hospital
    • Jiangsu
      • Suzhou, Jiangsu, China, 215000
        • Suzhou Guangji Hospital
      • Wuxi, Jiangsu, China, 214000
        • Wuxi Mental Health Center
    • Jiangxi
      • Nanchang, Jiangxi, China, 330038
        • Nanchang Mental Health Center
    • Jilin
      • Siping, Jilin, China, 136000
        • Jilin Provincial Neuropsychiatric Hospital
    • Shandong
      • Jinan, Shandong, China, 250014
        • Shongdong Mental Health Center
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200030
        • Shanghai Mental Health Center
    • Shanxi
      • Taiyuan, Shanxi, China, 030000
        • Frist Hospital of Shanxi Medical University
      • Xi’an, Shanxi, China, 710000
        • Xi'an Mental Health Center
    • Sichuan
      • Chengdu, Sichuan, China, 610072
        • Sichuan Provincial People's Hospital
      • Chengdu, Sichuan, China, 610000
        • The Fourth People's Hospital of Chengdu
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300000
        • Tianjin Anding Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310003
        • Hangzhou Seventh People's Hospital
      • Huzhou, Zhejiang, China, 313000
        • Huzhou Third Municipal Hospital
      • Ningbo, Zhejiang, China, 315000
        • The Affiliated Kangning Hospital of Ningbo University

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Male and female outpatients aged 18-65 years (inclusive).
  • Diagnosis of Major Depressive Disorder (MDD) according to DSM-5 criteria ( without psychotic features).
  • Hamilton Depression Rating Scale (HAM-D17) total score ≥ 22 at screening and baseline visits, with item 1 (depressed mood) score ≥ 2.
  • Clinical Global Impression-Severity (CGI-S) score ≥ 4 at screening and baseline.
  • Negative pregnancy test for women of childbearing potential.
  • Willingness to use effective contraception during the trial and for 3 months after the last dose.
  • Voluntary participation and signed informed consent.

Exclusion Criteria:

  • Duration of the current depressive episode in first-episode patients < 3 months.
  • Treatment-resistant depression (failure of ≥ 2 adequate antidepressant treatments).
  • Other psychiatric disorders (e.g., schizophrenia, bipolar disorder, anxiety disorders).
  • History of severe neurological diseases, epilepsy, or significant head trauma.
  • Unstable or severe cardiovascular, gastrointestinal, or endocrine diseases.
  • History of malignancy within the past 2 years.
  • History of increased intraocular pressure or untreated narrow-angle glaucoma.
  • Abnormal thyroid function not adequately controlled.
  • History of severe drug allergies or hypersensitivity to duloxetine or excipients.
  • Suicide attempt within the past year or significant suicide risk.
  • Substance abuse within the past year or positive at screening drug test.
  • Alcohol abuse (≥ 14 units/week) within the past year.
  • Previous treatment with duloxetine without adequate response.
  • Normative use of antidepressants within 2 weeks prior to screening.
  • Use of CYP2D6 or CYP1A2 potent inhibitors/inducers within 2 weeks prior to screening.
  • Participation in another clinical trial within the past 3 months.
  • Any condition deemed unsuitable by the investigator.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador de Placebo: Placebo

Matched dosing regimen.Twice daily for 6 weeks, followed by a 1-week tapering period.

Experimental: NH102 10mg

5 mg twice daily over 6 weeks, followed by a 1-week tapering period.

10 mg twice daily over 6 weeks, followed by a 1-week tapering period.

15 mg twice daily over 6 weeks, followed by a 1-week tapering period.

Experimental: NH102 20mg

5 mg twice daily over 6 weeks, followed by a 1-week tapering period.

10 mg twice daily over 6 weeks, followed by a 1-week tapering period.

15 mg twice daily over 6 weeks, followed by a 1-week tapering period.

Experimental: NH102 30mg

5 mg twice daily over 6 weeks, followed by a 1-week tapering period.

10 mg twice daily over 6 weeks, followed by a 1-week tapering period.

15 mg twice daily over 6 weeks, followed by a 1-week tapering period.

Comparador Ativo: Cápsulas entéricas de cloridrato de duloxetina

30 mg twice daily for 6 weeks, followed by a 1-week tapering period.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
17 items Hamilton Depression Scales (HAM-D17)
Prazo: 6 Weeks

Changes from baseline in the 17 items Hamilton Depression Scales (HAM-D17) total score at the end of treatment.

HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50. Higher scores indicate a worse outcome.

6 Weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
17 items Hamilton Depression Scales (HAM-D17)
Prazo: Week 2 and 4

Changes from baseline in the 17 items Hamilton Depression Scales (HAM-D17) total score at Week 2 and 4.

HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50. Higher scores indicate a worse outcome.

Week 2 and 4
Montgomery- Åsberg Depression Rating Scale(MADRS)
Prazo: 6 Weeks

Changes from baseline in the 10-items Montgomery- Åsberg Depression Scales (MADRS) total score at Week 2, Week 4 and the end of treatment.

MADRS is a standardized, clinician-administered rating scale that assesses 10 items characteristically associated with major depression. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

6 Weeks
Clinical Global Impression-Improvement (CGI-I)
Prazo: 6 Weeks

Changes from baseline in the CGI-I score at the end of treatment.

The Clinical Global Impression-Improvement (CGI-I) scale is a clinician-rated instrument designed to assess the overall improvement or worsening of a patient's condition relative to a baseline state. The following one query is rated on a seven-point scale: "Compared to the patient's condition at admission to the project, this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment."

6 Weeks
Clinical Global Impression-Severity (CGI-S)
Prazo: 6 Weeks

Changes from baseline in the Clinical Global Impression-Severity (CGI-S) score at the end of treatment.

The CGI-S asks the clinician one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.

6 Weeks
Hamilton Anxiety Rating Scale (HAM-A)
Prazo: 6 Weeks

Changes from baseline in the HAM-A total score at the end of treatment.

The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered assessment tool to measure the severity of anxiety symptoms. It consists of 14 items, each evaluating a specific symptom of anxiety, such as anxious mood, tension, fears, and somatic complaints. Each item is scored on a scale from 0 (None) to 4 ( Very severe. grossly disabling ), with the total score ranging from a minimum of 0 to a maximum of 56. Higher scores indicate greater severity of anxiety symptoms, reflecting a worse clinical outcome.

6 Weeks
Dimensional Anhedonia Rating Scale (DARS)
Prazo: 6 Weeks

Change from baseline in Dimensional Anhedonia Rating Scale (DARS) total score at the end of treatment.

The DARS is a self-report scale that measures anhedonia across the following 4 domains: hobbies/past-times, food/drinks, social activities, and sensory experiences. Within each domain, participants are required to provide at least two of their own examples of what they find rewarding. Subsequently, participants answer a set of standardized questions about desire, motivation, effort and consummatory pleasure for the examples provided. Responses were based on a 5-point Likert scale (Not at all=0; Slightly=1; Moderately=2; Mostly=3; Very Much=4), with the total score ranging from a minimum of 0 to a maximum of 68. A higher score reflects a better outcome.

6 Weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

4 de dezembro de 2024

Conclusão Primária (Real)

30 de julho de 2025

Conclusão do estudo (Real)

12 de setembro de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

16 de fevereiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

19 de fevereiro de 2025

Primeira postagem (Real)

24 de fevereiro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

20 de setembro de 2026

Última verificação

1 de novembro de 2025

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • NH102-21

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever